KDR and neoplasm: Anti-VEGFR-1-antibody treatment prevented the formation of lung pre-metastatic VEGFR-1+-HPCs clusters, consequent tumor cell recruitment, and metastasis formation, and anti-VEGFR-2-antibody treatment prevented large, well-vascularized metastases [104,105].